Q4 Results 2022: Key highlights of RITES, Metropolis Healthcare, JM Financial, Clariant Chemicals, Aster DM Healthcare March quarter results

Q4 Results 2022: Listed companies continue to announce their March quarter results. Some of the companies which declared results include RITES, Metropolis Healthcare, JM Financial, Clariant Chemicals (India) and Aster DM Healthcare. Here are key highlights of the quarterly earnings.

RITES Q4 results 2022: Railway consultancy firm posts Rs 142 crore profit in Q4

Railway consultancy firm RITES Ltd on Tuesday posted an almost flat profit of Rs 142.36 crore for the quarter ended March 2022.

The company had posted consolidated profit of Rs 141.55 crore in the year-ago period, RITES Ltd said in a regulatory filing.

The consolidated income of the company during the January-March period increased to Rs 787.52 crore over Rs 649.55 crore in the corresponding period of the previous fiscal, it added.

RITES Ltd is a multi-disciplinary consultancy organisation in the fields of transport, infrastructure and related technologies. 

RITES shares today ended at Rs 253.15 on the BSE and were up 0.18 per cent from the Monday closing price.

Metropolis Healthcare Q4 results 2022: quarterly profit declines 34% to Rs 40 cr

Diagnostic chain Metropolis Healthcare on Tuesday said its consolidated net profit has declined by 34 per cent to Rs 40 crore for the fourth quarter ended March.

The company had reported a net profit of Rs 61 crore in the January-March period of previous fiscal.

Revenue from operations stood at Rs 3,059 crore for the fourth quarter as against Rs 2,917 crore in the year-ago period, Metropolis Healthcare said in a regulatory filing.

For the fiscal year March 31, 2022, the company posted a consolidated net profit of Rs 215 crore, up 17 per cent from Rs 183 crore in 2020-21 fiscal.

Revenue from operations rose to Rs 1,228 crore from Rs 998 crore in FY21.

".. Inspite of all the challenges faced on account of COVID-led supply chain disruptions, we were able to record our highest ever revenue, EBITDA and PAT in FY22. Strong performance was on the back of robust growth in the sustainable non-COVID business," Metropolis Healthcare Promoter and Managing Director Ameera Shah said in a statement.

The company has made significant investments in digital, marketing, widening of leadership team and expansion of service network last fiscal, he added.

"These investments we make now will enable us to create a backbone for the next level of growth that we envisage in the business and help us safeguard our margins keeping in view the increased competitive intensity in coming times," Shah noted.

Going ahead, the company will continue to build the brand on scientific basis, invest in core focus areas and on the acquisition front, drive the synergies through quick and smooth integration, she said.

RITES shares today ended at Rs 253.15 on the BSE and were up 0.18 per cent from the Monday closing price.

See Zee Business Live TV Streaming Below:

JM Financial Q4 results 2022: net profit declines marginally to Rs 229 cr

JM Financial on Tuesday reported a marginal decline in its consolidated net profit at Rs 229 crore for the quarter ended March 2022.

It had posted a net profit of Rs 233 crore in the same period a year ago and Rs 261 crore in the preceding quarter ended December 2021.

Total income during January-March period of 2021-22 was also down at Rs 839 crore as against Rs 841 crore in the same quarter of 2020-21, JM Financial said in a regulatory filing.

Compared sequentially, the income was down by 13 per cent from Rs 964 crore in the December quarter of FY22.

The interest income of the non-banking financial company (NBFC) fell to Rs 422 crore during the quarter as against Rs 478 crore in year-ago period.

However, for the full year ended March 2022, the company's net profit rose by 23 per cent to Rs 992 crore from Rs 906 crore in the previous fiscal.

Total income was up by 16.6 per cent to Rs 3,763 crore from Rs 3,227 crore.

The board of directors of the company has recommended a final dividend of Rs 1.15 per share of Re 1 each, it said.

The dividend, if approved at the 37th annual general meeting, will result in cash outflow of Rs 109.75 crore, JM Financial said.

The company had paid an interim dividend of Rs 0.50 per share in March 2022.

With the final dividend, the total dividend for the financial year 2021-22 would be Rs 1.65 per share, aggregating to Rs 157.45 crore, it added.

Stock of JM Financial ended at Rs 64.65 apiece on BSE, down 1.97 per cent from the previous close. 

Clariant Chemicals Q4 results 2022: profit jumps up 47.67%

Clariant Chemicals (India) on Tuesday reported a 47.67 per cent growth in profit to Rs 16.20 crore for the January-March quarter of 2021-22 compared to the same period of the previous financial year.

The company's profit stood at Rs 10.97 crore during the corresponding quarter of 2020-21, Clariant Chemicals (India) said in a BSE filing.

Revenue from operations of the company declined by 4 per cent during the quarter under review to Rs 210 crore compared to Rs 218.84 crore in the same period of the previous fiscal.

For the 2021-22 fiscal, the company's profit plunged to Rs 43.32 crore from Rs 219.76 crore in FY21 mainly on account of exceptional items like sale of business units in the previous financial year.

Revenue from operations rose by 14.88 per cent to Rs 839.51 crore compared to Rs 730.77 crore in FY21.

Clariant Chemicals shares of the company on Tuesday closed at Rs 462.30, down 0.42 per cent on BSE.

Aster DM Healthcare Q4 results 2022: net jumps over two-fold to Rs 246 cr

Aster DM Healthcare on Tuesday said its consolidated net profit surged over two-fold to Rs 246 crore for the fourth quarter ended March 2022.

The healthcare provider had reported a net profit of Rs 117 crore in the January-March period of 2020-21 fiscal.

Revenue from operations rose to Rs 2,728 crore for the period under review from Rs 2,391 crore in the January-March quarter of FY21, Aster DM Healthcare said in a regulatory filing.

For the year ended March 31, 2022, the company posted a consolidated net profit of Rs 601 crore as compared to Rs 178 crore in 2020-21.

Revenue from operations rose to Rs 10,253 crore in the last fiscal as against Rs 8,608 crore in FY21.

"We have witnessed good overall growth during the recently concluded quarter. With existing facilities ramping up, there has been significant improvement in the utilisation of the facilities. Our India hospitals business is growing rapidly and we continue to add beds every quarter," Aster DM Healthcare Founder Chairman and Managing Director Azad Moopen noted.

The healthcare provider is actively exploring brownfield, low capex opportunities in various parts of India, which give a much better ROI and improve efficiencies, he added.

"Our diagnostics vertical, Aster Labs has now entered four other states: Maharashtra, Tamil Nadu, Andhra Pradesh and Telangana. Aster Pharmacy in India is expanding its footprint at a rapid pace with 131 stores having been opened as at March 31, 2022," Moopen added.

Aster DM Healthcare has presence in the Gulf Cooperation Council (GCC) region and India.